<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063163</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10-005-SCLC301</org_study_id>
    <nct_id>NCT04063163</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multicenter, phase III clinical study to compare the
      clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously
      Untreated Patients with Extensive Stage Small Cell Lung Cancer.

      Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

      Arm A (HLX10 arm): HLX10 + chemotherapy (Carboplatin-Etoposide) ; Arm B (placebo arm):
      Placebo + chemotherapy (Carboplatin-Etoposide); The three stratification factors for
      randomization include: PD-L1 expression level (negative, positive, not available), Brain
      metastasis (yes versus no), Age (≥ 65 years versus &lt; 65 years)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">December 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor assessment</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first(up to approximately 24months)</time_frame>
    <description>Progression-free survival (PFS) (assessed by the independent radiology review committee [IRRC] based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">489</enrollment>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX 10+chemotherapy (Carboplatin-Etoposide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo+chemotherapy (Carboplatin-Etoposide)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10</intervention_name>
    <description>HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin and etoposide</intervention_name>
    <description>chemotherapeutics</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans
             Administration Lung Study Group staging system).

          -  No prior systemic therapy for ES-SCLC

          -  Major organs are functioning well

          -  Participant must keep contraception

        Exclusion Criteria:

          -  Histologically or cytologically confirmed mixed SCLC.

          -  Known history of severe allergy to any monoclonal antibody.

          -  Known hypersensitivity to carboplatin or etoposide.

          -  Pregnant or breastfeeding females.

          -  Patients with a known history of psychotropic drug abuse or drug addiction.

          -  Patients who have other factors that could lead to the early termination of this study
             based on the investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Sun, PhD</last_name>
    <phone>1(713)4103224</phone>
    <email>dsun@henlius.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiong Wang, Master</last_name>
    <phone>+8618627113916</phone>
    <email>Qiong_Wang@henlius.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Wei</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Sun</last_name>
      <phone>1（713）4103224</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extensive Stage</keyword>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>Anti-PD-1 Monoclonal Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

